Stock Track | SBP GROUP Soars 5.39% Intraday on $1.9 Billion AstraZeneca Licensing Deal

Stock Track

Jul 08

SBP GROUP's stock surged 5.39% during intraday trading on Wednesday, following the announcement of a major licensing agreement with global pharmaceutical giant AstraZeneca.

The company has granted AstraZeneca exclusive rights to develop, manufacture and commercialize its self-developed PDE3/4 inhibitor TQC3721 outside China. Under the agreement, SBP GROUP is eligible to receive a $200 million upfront payment, with potential development, regulatory and sales milestone payments totaling up to $1.9 billion, plus tiered royalties based on annual net sales.

This represents the company's second major licensing deal with a multinational pharmaceutical firm this year and is expected to accelerate the global development of TQC3721 as a potential best-in-class therapy for chronic respiratory diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1145480782"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145480782\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145480782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145480782","market":"sg","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 5.39% Intraday on $1.9 Billion AstraZeneca Licensing Deal","media":"Stock Track","content":"<p>SBP GROUP's stock surged 5.39% during intraday trading on Wednesday, following the announcement of a major licensing agreement with global pharmaceutical giant AstraZeneca.</p><p>The company has granted AstraZeneca exclusive rights to develop, manufacture and commercialize its self-developed PDE3/4 inhibitor TQC3721 outside China. Under the agreement, SBP GROUP is eligible to receive a $200 million upfront payment, with potential development, regulatory and sales milestone payments totaling up to $1.9 billion, plus tiered royalties based on annual net sales.</p><p>This represents the company's second major licensing deal with a multinational pharmaceutical firm this year and is expected to accelerate the global development of TQC3721 as a potential best-in-class therapy for chronic respiratory diseases.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 5.39% Intraday on $1.9 Billion AstraZeneca Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 5.39% Intraday on $1.9 Billion AstraZeneca Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-08 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP's stock surged 5.39% during intraday trading on Wednesday, following the announcement of a major licensing agreement with global pharmaceutical giant AstraZeneca.</p><p>The company has granted AstraZeneca exclusive rights to develop, manufacture and commercialize its self-developed PDE3/4 inhibitor TQC3721 outside China. Under the agreement, SBP GROUP is eligible to receive a $200 million upfront payment, with potential development, regulatory and sales milestone payments totaling up to $1.9 billion, plus tiered royalties based on annual net sales.</p><p>This represents the company's second major licensing deal with a multinational pharmaceutical firm this year and is expected to accelerate the global development of TQC3721 as a potential best-in-class therapy for chronic respiratory diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1145480782","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145480782","pubTimestamp":1783474567,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock surged 5.39% during intraday trading on Wednesday, following the announcement of a major licensing agreement with global pharmaceutical giant AstraZeneca.The company has granted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股追踪|19亿美元阿斯利康授权交易SBP集团盘中大涨5.39%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock surged 5.39% during intraday trading on Wednesday, following the announcement of a major licensing agreement with global pharmaceutical giant AstraZeneca.The company has granted AstraZeneca exclusive rights to develop, manufacture and commercialize its self-developed PDE3/4 inhibitor TQC3721 outside China. Under the agreement, SBP GROUP is eligible to receive a $200 million upfront payment, with potential development, regulatory and sales milestone payments totaling up to $1.9 billion, plus tiered royalties based on annual net sales.This represents the company's second major licensing deal with a multinational pharmaceutical firm this year and is expected to accelerate the global development of TQC3721 as a potential best-in-class therapy for chronic respiratory diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}